Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Literature > Literature review > Flashcards

Literature review Flashcards

1
Q

Hallman et al 2018, Incidence and risk factors associated with development of clinical cardiooxicity in dogs receiving doxorubicin

How may developed cardiotoxicity?

List the 4 risk factors?

What was not associated with cardiotoxicity?

Incidence in high risk and low risk breeds?

A

4% (20/494 dogs)

Higher cumulative dose, high body weight, decreased in fractional shortening after 5 doses, and ventricular premature contractions

duration of DOX infusion

15.4% (high), 3% (low risk breeed)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Abma et al. 2018, A single dose of IV combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumor vascularization in canine spontaneous cancers

What is C4AP?

8 dogs with solid tumors were enrolled? Dose given?

Toxicity?

Cardiovascular changes noted?

Result?

A

Anti-tumor vascular agent that blocks tumor blood flow

single dose of 75 mg/m2

1 developed tetraparesis

Confined to HR and cTnI levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Epperly et al. Dogs with acute myeloid leukemia or lymphoid neoplasms (large cell lymphoma or acute lymphoblastic leukemia) may have indistinguisable mediastinal masses on radiographs

Medistinal mass was detected on radiographs in what % in lymphoid group and myeloid group?

What was the median size ratio of mediastinal mass to cardiac solhoutte in the 2 groups?

Normal thoracic radiorgaphs?

Conclusion?

A

73/218 (33%) lymphoid group and 9/20 (45%) in myeloid group

0.20 lyphoid group and 0.23 in myeloid group

111/218 (51%) in lymphoid and 9/20 (45%) in myeloid group

Consider acute myeloid leukemia if there is a mediastinal mass but size does not differentiate between lymphoud or myeloid neoplasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Magestro et al. 2017, Stereotactic body radiation therapy for heart-base tumors in 6 dogs

Dogs had presumed chemodectomas

How much did the tumor volume decrease?

Treatment related complications?

Major complication?

MST for dogs alive?

A

30-76% in 4 dogs

Cough, tachyarrythmias, CHF

2 dogs experienced sudden death at 150 and 295 days after SBRT

3 dogs alive 408-751 days (1-2 yr) and 1 dog 1228 days (3.4 yr)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Rohrer et al. 2018, Dosimetric benefit of adaptive radiotherapy in the neoadjuvant management of canine and feline thymoma - An exploratory case series

What is adaptive RT?

Rapid tumor shrinkage was observed when? Mean shrinkage? Tumor regression?

What was the OAR (organs at risk) to the heart and lungs?

A

Treatment plan is altered throughout the treatment course

1 week of therapy with mean shrinkage of 31% +/- 15.2% or tumor regression of 5.2% per day

After midtherapy planning, -18.2% in mean heart dose and -27.9% in V20 lung dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mullin et al. Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs

64 dogs treated with singl-agent DOX for presumptive cHSA

What was the objective response rate (CR + PR)?

Biological response rate (CR + PR+ SD) or clinical benefit?

MST compated to control dogs?

What was associated with improved PFS and OS?

What was negatively associated with PFS in univariate analysis?

A

41%

68%

116 days (4 mo) compared to 12 days for control dogs

Biologic response

Large tumor size

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Ployart et al. 2013, Thoracoscopic resection of right auricular masses in dogs: 9 cases (2003-2011)

What were the clinical signs?

Diagnosis?

Results?

A

8 dogs had clinical signs or cardiac tamponade and R-CHF

8 HSA and 1 pyogranulomatous lesion

8 lesions were removed and 1 dog died during surgery - Masses close to the base of the right atrial appendage may not be amenable to resection. Masses at the tip of the right auricular appendage can be removed by thoracospically

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Rancilio et al. 2012. Use of 3-dimensioanl conformal RT for treatment of a heart base chemodectoma in a dog

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Case et al. Outcome evaluation of a thoracoscopic pericardial window procedure or subtotal pericardectomy via thoracotomy for the treatment of pericardial effusion in dogs

58 dogs with pericardial effusion

Clinical signs?

DFI and MST for dogs with idiopathic pericardial effusion and neoplastic effusion

A

Similar except lethargy between gods treated wtih subtotal peri vis thoracotomy or the pericardial window procedure

Dogs with idiopathic pericardial effusion treated with thorascopic pericardial windown had shorter DFI and MST than those treated with thoracotomy - due to inaccuracy of initial diagnosis or ineffectiveness of peircardial window

No difference in DFI or MST in dogs with neoplastic pericardial effusion treated with either technique

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Atencia et al. Thoracoscopic pericardial windown for management of pericardial effusion in 15 dogs

Idiopathic pericardial effusion (n=10), cardiac mass (n=4) and mesothelioma (n=1)

Median thoracoscopic surgery time?

Complications? Median time to discharge?

MST for dogs with idiopathic pericardial effusion vs. neoplasia?

A

52.5 mins (45-80)

26% in 4 cases, 1 (1-6 days)

635 days or 1.7 yr (70-1165) vs. 30 days (1-107)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cote et al. 2013. Thoracic radiographic findings for dogs with cardiac tamponade atributable to pericardial effusion

50 dogs with cardiac tamponade (CT) and 23 control dogs (10 healthy and 13 with cardiac disease other than CT)

Sensitivity and specificity of enlargment of cardiac silhoutte with CT attributable to PE?

Sensitivity and specificity of globoid appearance for dogs with CT?

Sensitivity and specificity of a convex appearance?

A
  1. 6% and 47.8%
  2. 9% and 40%
  3. 1% and 35%

Thoracic radiographs should not be considered reliable for identification of dogs with CT?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Nolan et al. 2017. Pilot study to determine feasability of RT for dogs with right atrial masses and hemorrhagic pericardial effusion?

6 dogs with right atrial/auricular mass

Treatment related complications?

Pericardiocentesis performed before and after RT?

Pre- and post-treated plasma VEGF concentrations?

Cardiac troponin?

Median OST?

A

None

0.91x per weel before RT and 0.21x per week after RT

No different

Siginificant increases 4hr after irradiation

79 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Kelsey et al. 2017. Neuromuscular blocakge and inspiratory breath hold during stereotactic body radiation therapy for treatment of heart base tumors in 4 dogs

Neuromuscular blocake used?

Mean treatment delivery time? Mean anesthesia time?

A

Atracurium or vecuronium

26 minutes, 89 minutes

No hemoglobin destauration or hypercapnia

No complications noted

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Guglielmini et al. 2016. Sensitivity, specificity, and interobserver variability of survery thoracic radiography for the detection of heart base masses in dogs

30 dogs with HBM and 120 control dogs

Sensitivity of STR for diagnosis of HBM?

Specificity?

Results?

A

40% and 56.7% for observer A and 63% and 80% for observer B

96.7% for A and 99.2% and 92.5% for observer B

Survery thoracic radiographs (STR) are highly specific but not highly sensitive predictor for HBM in dogs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pedro et al. 2016. Cytological diagnosis of cardiac masses with ultrasound guided fine needle aspirates

6 cases identified

Ultrasound guided transthoracic FNAs performed

Complications noted?

Was a diagnosis obtained?

A

Mild self-limiting pericardial effusion (1) and ventricular ectopic complex (1)

Diagnosis confirmed in all cases: inflammation (1), HSA (2), sarcoma (1), and chemodectoma (1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Vognoli et al. 2013. Whole body CT characteristics of skeletal and cardiac muscular metastatic neoplasia in dogs and cats

Noted varying enhacement patterns, which was most common?

In 20 cases 2 or more lesions were observed

Location of muscular metastasis?

A

Ring enhancing (16), heterogeneously enhancing (8), homogeneously enhancing (5)

epaxial muscles of cervical, thoracic, and lumbar spine (18), superfical muscles of thoracic wall (13), scapular/shoulder area (3), hindlimbs (3), abdominal wall muscles (1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Ghaffari et al. 2014. A retropsective evaluation of doxorubicin-based chemotherapy for dogs with right atrial masses and pericardial effusion

MST for dogs that received doxorubicin?

Side effects?

A

139.5 days or 4.65 mo (2-302 days)

Frequent but mild

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Rajagopalan et al. 2013. Comparison of presumptive echocardiographic and definitive diagnosis of cardiac tumors in dogs

A total of 24 client owned dogs

Presumptive diagnosis of chemodectoma, ectopic thyroid CA, or LSA was correct in?

Presumptive diagnosis of HSA was correct in?

Pericardial effusion?

ECG abnormalities?

Survival?

A

7/9 cases (78%)

4/8 cases (50%)

10/24 cases (42%)

8/24 (33%)

<1 to >150 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Amati et al. 2014. Pericardial lymphoma in 7 cats

Clinical findings at presentation?

Thoracic imaging findings?

Immunophenotyping of 6 cats?

4 cats no tx, 1 prednisone, and 2 chemo - survival?

A

poor BCS, dehydration, dyspnea

pleural effusion, difffuse thickening of pericardium

3 were T cell and 3 B cell

6 cats 7-11 days, 1 cat that got chemo 750 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Lew eat al. 2019. Retrospective evaluation of canine heart base tumors treated with toceranib phosphate: 2011-2018

28 dogs with HBT

What was the overall response rate?

Overall MST?

Overall response rate for presenting with metastasis and MST?

How may had improvement in CS?

Toxicity?

A

10%

823 days (2.2 yr)

28.5% and 532 days (1.5 y)

90% had improvement and 81% had complete resolution

54% and mostly GI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Saba et al. Indirect assessment of dihydropyrimidine dehydrogenase activiy in cats

Determinined uracil:dihydrouracil (U:UH2) in plasma using HPLC in 73 cats

What was the mean U:UH2?

How may had >2 - assocaited with decreased DPD activity in humans?

Who had lower levels?

A

1.66

23%

SF cats had lower compared to FI and age was weakly but significantly correlated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Wypij et al. Pamidronate disodium for palliative therapy for feline bone-invasive tumors

8 cats treated with IV pamidronate - 1 cat in combination with chemo and 2 cats as single agent, what was the median PFI?

Side effects noted?

What was median overall survival? for cats with SCC?

What was median PFS for all cats? SCC?

A

81 days

3 cats developed azotemia (37.5%)

116.5 days, 170 days

55 days, 71 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Hafeman et al. Bisphosphanates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells

The combination of what 2 drugs was associated with synergistic killing and increase in cell cycle arrest?

What other combination increased cell killing? What was the mechanism?

A

Clodronate and vincristine

Zoledronate and doxorubicin, zoledronate increased uptake of doxorubicin by MH cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Pan et al. Safety evaluation of combination CCNU and continuous toceranib in tumor bearing dogs: a phase I dose-finding study

What was the DLT for the combination? What the MTD for CCNU?

What was the objective response rate? Biologic response rate?

A

neutropenia, 50 mg/m2 q3wk

38.4% and 53.8%

Combination was well tolerated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Musser et al. Low apparent risk of CCNU-associated clinical hepatotoxicity in cats

CCNU given as single agent 31-60 mg/m2 once every 4-8 weeks

How may cats developed elevation in ALT after treatment?

How many cats developed hepatotoxicity?

Any association between dosing frquency, cumulative dose, initial starting dose, or concurrent medications and increase in ALT?

A

2 cats (6.8%) 1 month after tx with CCNU

1 cat without elevation in ALT

None were found.

Hepatic injury is uncommon in cats with CCNU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Best et al. 2013. Incidence of sterile hemorrhagic cystitis in dogs receiving cyclophosphamide orally for 3 days without concurrrent furosemide as part of a chemotherapeutic treatment for lymphoma: 57 cases (2007-2012)

How many developed SHC?

How may developed myelosuppression? GI efffects?

A

None

None, 5 had mild

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Gaeta et al. Risk factors for development of steril hemorrhagic cystitis in canine LSA patients receiving oral cyclophosphamide: a case-control study

22 dogs with SHC and 66 control dgos were identified

On univariable analysis, what were the risk factors for SHC?

On multivariable analysis? Decreased risk?

SHC is a delayed toxicity associated with high cumulative doses

A

Age, induction protocol, and cumulative dose were associated with increased risk.

Increasing cumulative dose was associated with increased risk. Short induction protocol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Marrington et al. Toxicity associated with epirubicin treatments in a large case series of dogs

Epirubicin is a stereoisomer of?

What were the most common toxicity?

What reduced dose toxicity?

Did prophylactic anti-emetics, gaatroproectants, and antibiotics reduce the frequency of GI toxicity?

A

Doxorubicin

lethargy (50), diarrhea (49), vomiting (42), anorexia (40), hypersensitivity (2), extravasation (2)

Dose reductions

They did not.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Venable et al. Dexrazoxane treatment of doxorubicin extravasation injury in four dogs?

Signs noted at extravasation site in dogs treated within 2 hrs? Treated in 48 hours?

Outcome for the 3 dogs and 1 dog?

A

Mild erythema and edema developed within 1 hours to 6 days in 3 dogs that received zinecard within 2 hrs after extravasation. Extensive tissue necrosis

Surgical intervention for dog with tissue necrosis and the other 3 dogs lesions resolved on medical management.

Treat with dexrazoxane within 6 hours of extravasation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Ratteree et al. 2012. Value of echocardiography and electrocardiography as screening tools prior to doxorubicin administration

Of the 101 dogs, how many were excluded from doxorubicin administration?

What were the most common arrythmias?

What was the incidence of cardiotoxicity in treated dogs?

A

6 dogs (6%) were exluded

Ventricual premature contractions

8%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Wittenburg et al. Development of a limited sampling model for prediction of doxorubicin exposure in dogs.

3 blood samples are obtained over 1 hours post-treatment that accurately predict patient exposure

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Rasmussen et al. Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol on tumor-bearing dogs

What happened to circulating lymphocytes in dogs receiving combination DOX/mCTX and single agent DOX?

How were the depletions between the 2 groups?

A

Significant depletion of circulating lymphocytes without selectivity for Tregs

Depletion were similar between dogs in dogs reciving DOX or DOX/mCTX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Tater et al. Assessment of cardian troponin I and tissue velocity imaging in 14 dogs with malignant lymphoma undergoing chemotherapy treatment with doxorubicin

Echocardiographsic measurement and cTn1 levels were obstained before and after doxorubicin in 14 dogs

What was concluded about echocardiographic parameters, tissue Doppler indices, and cTnI concerntrations?

A

Did not differ at any point in a 12-week protocol

Doxorubicin may not be associated with significant myocardial damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Marconato et al. An Open-label Phase 1 dose escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors

22 client owned dogs. Treated at 4 dose levels ranging from 800-950 mg/m2 (escalation of 50 mg/m2).

What was the DLT? What was MTD?

At 900mg/m2 what responses were observed?

What is the recommended dose for future Phase 2 studies?

A

Neutropenia. 900 mg/m2

2 CR and 5 PR

900 mg/m2 once weekly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Leach et al. Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occuring cancer

36 dogs given chlorambucil at 4mg/m2

What was the overall remission rate? CR and PR?

What was the median PFI? MST?

A

11% (3 CRs with MCT, STS, and thyroid carcinoma) that lasted 35 weeks

PR in 1 dog with histiocytic sarcoma (39 weeks survival)

61 days (2 mo), 153 days (5 mo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Leo et al. Evaluation of low-dose metronomic cyclophosphamide toxicity in cats with malignant neoplasia

24 cats with variety of neoplasms (13 sarcomas, 12 carcinomas, 1 melanoma, 1 neuroendocrine tumor)

What was noted in the 1st month of treatment? Other toxicites noted?

Toxicities noted at 2 months?

A

GI toxicity. 2/24 (8%) grade I hematological toxicity and 1/24 (4%) grade I renal toxicity

2 grade III and 1 grade I renal azotemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Larson et al. 2015. PK of orally administered low-dose rapamycin in healthy dogs

5 healthy dogs

Oral administration of low-dose (0.1 mg/kg) rapamycin achieved blood concentrations in ____ per mililiter?

A

nanograms per milliliter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Frazier et al. Phase I clinical trial of oral rosiglitazone in combination with IV carboplatin in cancer bearing dogs

What is rosiglitazone?

What was the DLT and dose (6-8 mg/m2)?

Changes in liver values?

A

Peroxisome proliferator-activated receptor gamma (PPARg) agonist and antidiabetic agent - reduce tumor cell growth

Hepatic and 8 mg/m2

Mild to moderate elevations in ALT, no changes with ALP, tbili, or GGT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Waite et al. 2011. Phase II study of oral docataxel and cyclosporine in canine epithelial cancer

51 dogs enrolled.

What was the overall response rate? Highest response rate was seen in who?

Main toxicity noted?

A

17%. 50% response rate in dogs with oral SCC

GI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Vail et al. 2012. A randomized trial investigating the efficacy and safety of water soluble Paclitaxel (Paccal Vet) for treatment if nonresectable grade 2 or 3 MCT in Dogs

250 dogs with nonresectable grade 2 or 3 MCT

What was the overall CORR (confimred overall response rate) and BORR compared to lomustine?

Paclitaxel treated dogs were __x more likely to have responsd and __x more like to experience bologic observed response?

Toxicities?

A

7% vs 1% and 23% vs. 10%

6.5x, 3.1x

33% receiving lomustine were d/c due to hepatopathy and 2% receiving paclitaxel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

H. von Euler. A dose finding study with novel water soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumors in dogs

What was the ORR, median time to response, and median PFS?

What was the associated AE?

A

86%, 14 days, and 131 days

Myelosuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

Kim et al. 2015. Exploration of paclitaxel as treatment for malignant tumors in cats: a descriptive case series

9 cats treated at 80 mg/m2 IV every 21 days upto 2 doses

AEs?

Response rate?

Median TTP

A

thrombocytopenia, GI signs, hypersensitivity (5)

SD and PR in 56%

28 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Gagnon et al. 2015. Treatment-related toxicites in tumor bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment

TMZ orally once for 5 days every 3 weeks at 20mg/cat with various malignancies in 10 cats

Response noted in 8 cats?

Toxicity noted in cats?

A

2 CR, 1 SD, 5 PR

Effusion with higher cumulative dose of TMZ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Mitchell et al. 2012. Clinical and Immunomodulatory effects if Toceranib Combined with Low-dose cyclophosphamide in dogs with cancer

15 client owned dogs with advanced tumors

What happened to Tregs and IFN-g?

A

Toceranib decreased percentage of Tregs in peripheral blood.

Dogs receiving toceranib and cytoxan had increase in IFN-g whihc was inversely correlated with Treg after 6 weeks of combination treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

London et al. 2012 Preliminary evidence for biologic activity of toceranib phosphate in solid tumors

Clinical benefit was noted in how many dogs?

AGASACA?

OSA?

Thyroid carcinoma?

Head and neck carcinoma?

Nasal carcinoma?

A

74%

28/32 = 87% AGASACA

11/23 = 23% OSA

12/15= 80% Thyroid

7/8 = 87.5%

5/7 = 71% nasal carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Chon et al. Safety evaluation of combination toceranib phosphate and piroxicam in tumor-bearing dogs (exclusing MCTs): a phase I dose finding study

Dosage recommendations for both drugs?

A

Standard dosage of both drugs (3.25 mg/kg EOD and piroxicam 0.3 mg/kg/day) was safe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Robat et al. Safety evaluation of combination vinblastine and toceranib phosphate in dogs: a phase I dose-finding study

DLT for combination?

MTD for vinblastine?

What was the observed objective response?

A

Neutropenia

1.6 mg/m2 every other week with toceranib 3.25 mg/kg EOD

50% dose reduction with vinblastine does not support combination

71% objective response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Achanta et al. Reaction phenotyping of vinblastine metabolism in dogs

What is the major cytochrome P450 isoform for the metabolism in dogs?

A

CYP3A12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Lind et al. 2013. Evaluation of vincristine associated myelosuppression (VAM) in Border Collies

How may developed VAM of the 5 Border Collies?

What was identified in these border collies?

A

3/5 (60%) border collies with ABCB1 wildtype developed VAM.

8 single nucleotide polymorphisms in ABCB1 were detected

50
Q

Pierro et al. 2013. Phase I clinical trial of vinorelbine in tumor bearing cats

19 cats enrolled in study

What was the MTD in cats?

Acute DLT?

A

11.5 mg/m2 once weekly- maximum dosage administered was 15.5 mg/m2

Neutropenia, vomiting, nephrotoxicity

51
Q

Wouda et al. 2015. Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997-2012)

CR?

PR?

SD?

PD?

Median time to tumor progression?

A

2% for 162 days

11% for 91 days

43% 68 days

43% for 21 days

103 days

52
Q

Heyden et al. 2012. Influence of P-glycoprotein modulation on plasma concentrations and PK or orally administered prednisolone in dogs

What does Rifampin and ketoconazole do to P-gp?

What did Rifampin tx do?

What did ketoconazole do?

A

Rifampin is an inducer of P-gp and ketoconazole in an inhibitor of P-gp

Upregulated duodenal P-gp and reduced the AUC of prednisolone

Downreulated duodenal P-gp and increased the AUC of prednisolone

53
Q

Silver et al. 2012. Evaluation of oral antimitotic agent (ABT-751) in dogs with lymphoma

What is ABT-751?

31 dogs with naive (19) or relapsed non-Hodgkin’s LSA (11)

What was the MTD?

DLT?

What was the objective response and response of duration?

A

antimitotic agent that targets MT polymerization

350mg/m2 PO Q24hr

vomiting, diarrhea - improved if given 48hr

20% and 21 to 111 days

54
Q

Vail et al. 2012: Phase I study to determine MTD and DLT of orally administered Idarubicin in Dogs with LSA

What was the MTD in dogs > 15 kg?

DLT?

A

22 mg/m2

Neutropenia and thrombocytopenia

55
Q

Meier et al. 2013. Use of Epothilone B (Ptupilone) in refractory lymphoma and advanced solid tumors in dogs

What are epothilone?

20 dogs with various malignancies

Canine HSA and lymphoma cell lines, what was noted?

Main AEs?

MTD in dogs?

A

Mictorubule stabilizing agent

50% decrease in proliferative activity

diarrhea, anorexia, vomiting, nausea

2.76 mg/m2 IV once weekly

56
Q

Cora et al. 2013. Comparison of automated versus manual neutrophil counts for the detection of cellular abnormaltiies in dogs receiving chemotherapy: 50 cases

What was the correlation coefficient of the neutrophil count?

A

0.96

57
Q

LeBlanc et al. Serial evaluation of neutrophil function in tumor bearing dogs undergoing chemotherapy

Flow cytometry used to asses neutrophil oxidative burst and phagocytic activites at baseline, 7 and 21 days after induction chemotherapy in 20 dogs with LSA

Dogs had ___ percentage of neutrophils exhibiting oxidative burst after stimulation with E. coli and PMA at 7 days

Induction chemotherapy suppresses percentage of neutrophils oxidative burst with improvement over time

A

lower

58
Q

Janssens et al. Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs

What is the major route of elimination of Pt in dogs?

How else does excretion occur and for how long?

Pt excretion can be found for how long?

A

Urine

Feces and saliva with highest amount during the first 5 days

Upto 21 days

59
Q

Kidd et al. Development of ELISA to detect circulating anti-asparaginase antibiodies in dogs with lymphoid neoplasia treated with E. coli L-asparaginase

How many dogs developed titers after single injection in 10 dogs?

With repeated exposires in 7 dogs?

A

3/10 (30%)

4/7 (57%)

60
Q

Britton et al. Evaluation of factors associayed with prolonged hospital stay and outcome of febrile neutropenic patients reciving chemotherapy: 70 cases (1997-2010)

Majority of patients recieved what chemo?

What factors were associated with long hospital stay?

What were associated with death in hospital?

A

70% got vincristine or doxorubicin prior to FN

Tachycardia at admission, complicating medical issues, G-CSF

Hypotension and G-CSF

61
Q

Mason et al. Gastrointestinal toxicity after vincrsitine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study

Was there a difference in vomiting, diarrhea, appetite loss, or lethargy between dogs that got cerenia or did not?

A

Cerenia did not reduce the frequency of AEs and should only be given as required

62
Q

Genoni et al. Safety of intrathecal administration of cytosine arabinoside and methotrexate in dogs and cats

How many developed side effects?

Is it safe?

A

1 dog developed tonic-clonic seizure after cytosar and methotrexate administration and responsed to diazepam

Very safe :)

63
Q

Kicenuik et al. Treatment time, ease of use and cost associated with use of Equashiled, Phaseal, or no closed system transfer device for administration of cancer chemotherapy to a dog model

Administration was fastest with?

Which was easier to use?

Which cost less?

A

Equashiled

Equashiled was easier to use than Phaseal or CSTD (closed system trasnfer device)

Equashiled cost less but sold in bulk

64
Q

Fulkerson et al. PK and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs

What is zebularine?

Cmax?

Mean half-life?

Which dose resulted in AEs?

A

Oral cytidine analog wuth demethylating activity

23 and 8.6 with 8 and 4 mg/kg dose

5.7 and 7.1 with 8 and 4 mg/kg dose

Single 8 mg/kg dose was well tolerated. Daily 4 mg/kg caused neutropenia, anorexia, dermatologic changes

65
Q

Finlay et al. Evaluation of the risks of chemotherapy in dogs with thrombocytopenia

Was there any difference in AEs in dogs with thrombotyoepnia?

A

No statistically significant difference in incidence of GI AEs or hemorrhage between thrombocytopenic and control dogs

66
Q

Moretti et al. Nucleated erythrocytes in blood smears of dogs undergoing chemotherapy

A
67
Q

Sthanasiadi et a. Safety, tolerability and PK properties of the novel triazene Trin 2755 in tumor bearing dogs

A
68
Q

Lewis et al. Comparison of chemotherapeutic drug resistance in cells transfected with canine ABCG2 or feline ABCG2

Goal to compare canine ABCG2-mediated drug resistance to feline ABCG2

HEK293 cells were transfected with canine, feline, or no ABCG2 and exposed to carbo, DOX, mitox, toceranib, or vincristine

Canine conferred more resistance than feline to what drug?

Neither conferred resistance to what drug?

Canine conferred resistance but not feline to?

A

Mitoxantrone

DOX, Vinc, toceranib

Carbo - drug not a substrate for ABCG2

69
Q

Guth et al. Liposomal clodronate treatment for tumor macrophage depletion in dogs with STS

Tumor related macrophages correlate with tumor growth.

13 dogs with STS

5/13 dogs density of _____ macrophages were decreased after LC treatment

Circulating concentrations of ____ were also decreased

A

CD11b+, IL-8

70
Q

Bavcar et al. 2017. Combination toceranib and lomustine shows freqeunt high grade toxicities when used for treatment of non-resectable or recurrent MCT in dogs

10 dogs with advanced MCT and treated with toceraniv 2.7 mg/kg EOD, lomustine 60 mg/m2 q3wk, prednisolone 1 mg/kg EOD alternating with toceranib

Objective RR?

AEs?

A

50%

All dogs had AEs, 3 dogs died and trial was stopped :(

71
Q

Laprais et al. 2017. Is CCNU valuable for treatment of cutaneous epitheliotropic LSA in dogs?

Which drugs have the highest rate of CR?

MST w/o tx?

MST with CCNU protocol?

MST with retinoids, PEG ELSPAR, prednisolone monotherapy?

A

CCNU and pegylated liposomal DOX in 1/3 of dogs

3 to 5 months

6 months

11 months, 9 months, 4 months

72
Q

Pierro et al. 2017. Febrile neutropenia in cats treated with chemotherapy.

22 FN events in 20 cats

Most common diagnosis?

Most common agents?

CS?

Median # of days betweem chemo and FN?

A

LSA

Vinca alkaloids and lomustine

Anorexia, lethargy, vomiting, diarrhea

5 days, tx with IV fluids and antibiotics

73
Q

Burton et al. 2016. Frequency and severity of neutropenia associatyed with FDA approved and compounded formulation of lomustine in dogs with cancer.

37 dogs treated with FDA approved or compounded lomustine

21 dogs recived FDA approved and 16 dogs from compounding pharmacy

Neutropenia in FDA approved?

Neutropenia in compounded lomustine?

A

All dogs were neutropenic. 71% had grade 3 or higher neutropenia

25% were neutropenic with 12.5% grade 3 neeutropenia

Potency of lomustine from 5 pharmacies ranged from 50-115% with 1 sample within +/- 10%

74
Q

Chakkath et al. 2015. Alkylation and Carbamylation Effects of Lomustine and its major metabolites and MGMT expression in canine cells

Low MGMT expression in canine lymphoiud cell line 17-71 while GL-1 cells dont

A
75
Q

Halsey et al. 2014. Development of an in vitro model of acquired resistance to toceranib phosphate in canine MCT

A
76
Q

Rassnick et al. 2014. Tolerability of lomustine in combination with cyclophosphamide in dogs with LSA

CCNU given 60 mg/m2 on day 0, CTX given 250 mg/m2 divided over day 0-4, antibiotics

Main toxic effect? Frequency of grade 4 neutropenia

A

Neutropenia, 30%

Mean body weight of dogs that developed grade 4 neutropenia was less (20kg) than those that did not develop grade 4 neutropenia (32kg)

Dose of CCNU combined with CTX every 4 weeks is tolerable

77
Q

Meervenne et al. 2014. Comparison between symptomatic treatment and lomustine supplementation in 71 dogs with intracranial, space occupying lesions

15 dogs tx with steroids and anti-epileptics, 56 dogs recived addition al tx with lomustine

MST b/w the 2 groups?

What affected survival time?

A

No difference, 60 and 93 days

Female dogs survived longer than male dogs

78
Q

Dutelle et al. 2012. Evaluation of lomustine as a rescue agents for cats with resistant LSA

39 cats with resistant LSA

What were the significant prognostic factors for PFI?

Overall PFI?

MPFI for large versus small and intermediate cell LSA

MPFI for GI versus non-GI LSA

A

Cell size, # of previous chemotherapy drugs, # of previous chemo protocols, and anatomic location of LSA

39 days

21 vs. 169 days

180 vs. 25 days

79
Q

Saba et al. 2012. Phase II clinical evaluation of lomustine chemotherapy for feline vaccine-associated sarcoma

28 cats with measurable VAS

Overall RR?

Median PFS and median duration of response?

Common toxicity?

A

25%

60.5 and 82.5 days

Neutropenia

80
Q

Bergman et al. 2016. Evaluation of local toxic effects and outcomes for dogs undergoing marginal tumor excision with intralesional cisplatin-impregnated bead placement for treatment of STS: 62 cases (2009-2012)

How many had toxicosis at bead placement?

Median DFI in grade 1, 2 and 3

Disease free survival rates with grade 1, 2, and 3?

A

71% (24/51)

Not reached for grade 1 and 2, 148 days with grade 3

88%, 75%, and 64%

81
Q

Kenward et al. Anti-nausea effects and PK of ondansetron, maropitamt. amd metoclopramide in a low-dose cisplatin model of nausea and vomiting in dog: a bling crossover study

Placebo treated group vomited?

Ondansetron or maropitant group?

Metoclopramide?

AVP (arginine vasopression) and cortisol were prevented by?

The drug with greated anti-emetic and anti-nausea efficacy?

A

7 times

Did not vomit

No effect on vomiting or nausea

Ondansetron and partially by maropitant (NK1 antagonist), metoclopramide (D2 antagonist) had no effect

Ondansetron (5-HT3 antagonist)

82
Q

Michalowsska et al. 2014. Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treate spontaneous canine tumors

Encapsulated cells overexpressing cytochrome P450 enzyme isoform 2B1 were implanted around malignant mammary tumors. Dogs were given cyclophosphamide.

Reduction in tumors?

Tumors that received cyclophosphamide alone?

Take home?

A

50% (6/11)

SD

Encapsulated c ytochrome P450 combined with chemo may be useful in treatment of mammary tumors

83
Q

Denies et al. Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients

10 healthy dogs and 30 canine cancer patients

Percentage of Tregs in cancer patent and healthy dogs?

Treatment with temozolomide and Tregs?

TSP-1 and VEGF levels?

A

Decrease in Tegs in patients with metronomic cyclophposphamide and combination.

No effect of Tregs

Lower in cancer patients and higher in healhty dogs but not influence by metronomic regimens

84
Q

Robat et al. 2017. Potency and stability of compounded cyclophosphamide: a pilot study

Obtained 15mg cyclophosphamide capsules from 5 pharmacies and did potency analysis at 2 timepoints.

Potency results?

Stability?

A

Inadequate

Adequte at 60 days except for 1 sample

85
Q

Chan et al. 2016, Incidence of sterile hemorrhagic cystitis in tumoe bearing dogs concurrently treated with an oral metronomic cyclophosphamide chemotherapy and furosemide: 55 cases (2009-2015)

SHC was how common?

A

Identified in 2/55 (3.6%)

Low inicidence of SHC, furosemide may protect against SHC

86
Q

Matsuyama et al. 2017. Evaluation of toxicity of a chronic alternate day metronomic cyclophosphamode chemotherapy protocol in dogs with naturally occuring cancer

50 dogs with median lenght of treatment of 90 days

Treatment was discontinued in how many?

How many developed SHC? Median time?

What was associated with higher risk of SHC?

A

22/50 - 44% due to AEs

16 dogs (32%), 130 days

higher cumulative dose

87
Q

Burton et al. 2017. Potency and stability of compounded formulations of chlorambucil, melphalan, and cyclophosphamide

Compounded 1 mg CHB, CTX 5mg, melphalan 1 mg

Potency of CHB?

Melphalan?

At 6 weeks?

Cyclophosphamide?

A

71-104%

58-109%

<90% strenght at baseline and 6 weeks

92-107%

Variability of compounded chemotherary products, need to consider potency and stability

88
Q

Harper et al. Toxicity of metronomic cyclophosphamide chemotherapy in UK population of cancer bearing dogs: a retropsective study

Included 65 dogs

cyclophosphamide between 5-15 mg/m2/day or EOD

How frequent was toxicity? What were the 2 common toxicities?

Median time to development of SHC?

A

49%. SHC (25%, 16) and GI (18%, 12)

110 days

89
Q

Setyo et al. 2017. Furosemide for prevention of cyclophosphamide-associated strile hemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide

115 dogs treated with metronomic cyclophosphamide

Incidence of SHC?

Incidence of SHC with and w/o furosemide?

Other risk factors associated with SHC?

A

21.7% (25 dogs)

10% and 30%

None

Furosemide is effective in preventing SHC

90
Q

Stroda et al. 2017. PK of cyclophosphamide and 4-hydroxycyclophosphamide in cats after oral, IV, and IP administration

6 healthy cats - 200 mg/m2 via each route (oral, IV, IP)

PK for the 3 routes?

AUC?

Toxicity?

A

Similar regardless of route

Lower for oral route

Well tolerated

91
Q

Pellin et al. 2017. Safety evaluation of combination doxorubicin and toceranib phosphate in tumor bearing dogs? a phase I finding study

DLT?

MTD for both drugs?

AEs?

A

Neutropenia

25 mg/m2 IV q21 days and 2.75 mg/kg EOD

None

Warrants further investigation in phase II/III trials

92
Q

Thornton et al. 2017. Owner perceptions of their cats quality of life when treated with a modified University of Wisconsin-Madison protocol for LSA

Postal questionare sent to owners of 33 cats

Median quality of life score before and after diagnosis? During chemotherapy

Quality of life scores correlated with?

A

10, 3, 7

Appetite

Most owenrs were happy their cat was treated (75%)

93
Q

Garnett et al. 2016. Fixed-dose rate administration of gemcitabine in cancer bearing cats: A pilot study

Cats treated with <2.5 mg/m2?

10 mg/m2?

Best dose?

A

Failed to achieve target plasma concentration (TPC)

Exceeded TPC

2-5 mg/m2

94
Q

Batchinski et al. 2014. Evaluation of ifosfamide salvage therapy for metastatic canine OSA

19 included and 17 evaluated for response

Overall response?

Median survival duration?

A

11.8% (1/17 CR, 1/17 PR, 2/17 SD, 13/17 PD)

95 days

95
Q

Custead et al. 2017. Retrospective comparison of three doses of metronomic chlormabucil for tolerability and efficacy in dogs with spontaneous cancer

88 dogs comparing 3 doses of CHB at 4, 6, 8 mg/m2

Toxicity at 6 mg/m2?

8 mg/m2?

A

Severity of GI signs was worse and development of GI was shorter compared to 4 mg/m2

Thrombocytopenia ocurred earlier at 8 than 4 mg/m2

Higher doses did not provide improved responses and were associated with more AEs

96
Q

Rivera et al. 2013. Clinical efficay and safty of water-soluble micellar paclitaxel in canine mastocytomas

Paccal Vet administred at 145 mg/m2 IV q21 days for 3 cycles to 29 dogs

CR and PR?

Median time to progression?

Side effects?

A

59%

247 days (8.2 mo)

grade 3/4 neutropenia and garde 1/2 leukopenia in majority of dogs

97
Q

Lyles et al. 2012. In vitro effects of tyrosine kinase inhibitor, masitinib mesylate, on canine HSA cell linces

Masnitib causes dose-dependent HSA cell death with activation of caspase 3/7

Increase in VEGF in proximity to IC50 (50% inhibitory concentration)

A
98
Q

Smrkovski et al. 2015. Masitinib mesylate for metastatic and non-resectable canine cutaneous MCT

26 dogs included in study

Overal RR?

MST for responders and non-responders?

Toxicity?

Most significant prognostic factor?

A

50%

630 days (1.7 yr) vs. 137 days (4.6 mo)

61.5% which were mild and self-limiting

Response to masitnib and not tumor grade, stage or location

99
Q

Holtermann et al. 2016. Masitinib monotherapy in canine epitheliotrophic LSA

CR noted in how may dogs?

KIT expression? SCF? PDGF

A

2/10

Negative, 6/8 positive, 2/8

Effective in treating LSA but effects not mediated through KIT receptor

100
Q

Grant et al. 2016. Clinical response of masitinib mesylate in the treatment of canine macroscopic MCT

39 dogs treated with masitinib for macroscopic MCT

Clinical response rate? CR and PR?

Median time to progression?

AEs?

MST?

A

82%, 15 CR (38.5%) and 17 PR (44%)

80 days

64% with serum ALT elevation (23%) and vomiting (15%)

159 days

101
Q

Leblanc et al., 2012. Preliminary evaluation of serial (18) FDG-PET?CT to assess response to toceranib phosphate therapy in canine canine

6 dogs

A
102
Q

Bernabe et al. 2013. Evaluation of the AE profile and PD of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose

Toceranib given at 2.5-2.75 mg/kg EOD and measured plasma toceranib and VEGF concentrations on days 0, 7, 14, 30

A

Resulted in 6-8 hr plasma concentration of 100-200 ng/ml, aboe the 40 ng/ml concentration needed for target inhibition

VEGF concentration increased significantly ovet the 30 day treatment period indicating VEGFR2 inhibition

Associated with lower AEs compared to the 3.35 mg/kg EOD labeled dose

103
Q

Merrick et al. 2017. Retrospective evaluation of toceranib phosphate toxicity in cats.

55 cats and 55% had carcinoma

Median dose of 2.7 mg/kg given M,W,F

Common hematological toxicity?

Common biochemical alteration?

GI toxicity?

A

Thrombocytopenia (16%) and neutropenia (9%)

Azotemia (14%) and ALT elevation (7%)

21.8% - much lower than dogs

104
Q

Harper et al. 2017. Toxicity and response in cats with neoplasia treated with toceranib phosphate

14 cats and were previously treated (surgery, RT, chemo) with epithelial tumors or MCTs

Toxicity?

Biological response?

Median duration of response?

A

10/14 cats - myelosuppression and GI, 2 developed severe hepatotoxicity

57.1%

90 days - no response in cats with SCC

105
Q

Tjostheim et al. 2016. Effects of toceranib phosphate on systolic blood pressure and proteinuria in dogs

26 control dogs and 30 dogs with cancer

Systolic blood pressure?

Prevalence of systemic hypertension and proteinuria in treatment dogs?

A

Higher after initiation of treatment

37% and 21% comapred to 15% and 0% in healthy dogs

106
Q

Wouda et al. 2018. Safety evaluation of combination carboplatin and toceranib phosphate in tumor bearing dogs: a phase I dose finding study

Toceranib 2.7 mg/kg EOD and carboplatin 200 mg/me IV q 21 days in 11 dogs

MTD for both drugs?

DLT?

Response?

A

Toceranib 2.7 mg/kg EOD and carboplatin 200 mg/me IV q 21 days

Neutropenia

2 PR, 6 SD

107
Q

Hume et al. 2018. Effects of toecranib phosphate on hypothalmic-pituitary-thyroid axis in tumor bearing dogs

Thyroid dysfunction is assocaited with use in people

43 dogs

Toceranib can disrupt the thyoid axis in dogs and TT4, fT4, TT3, TSH should be monitored

A
108
Q

Teske et al. 2014. Intraperitoneal antineoplastic drug delivery: experience with a cyclophosphamide, vincristine, and prednisolone protocol in cats with malignant LSA

26 cats with malignant lymphoma received IP-COP

CR rate?

Median duration of first remission? 1- and 2- year survival?

A

77% (n=20)

420 days, 67% and 48%

Young cats more favourable prognosis and achieving CR was essential for long term survival

No IP AEs

109
Q

Collicutt et al. 2013. Erythrocyte dysplasia in peripheral blood smears from 6 thrombocytopenic dogs treated with vincristine sulfate

19 dogs got vinc for IMT

2/5 had evidence of erythrodysplasia

Clincially insignificant

A
110
Q

Cai et al. 2017. Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors

18 rats, 9 mice, and 16 dogs with cancer

A
111
Q

Plasma cytokeratin-18 concentrations as nonivasive biomarkers of early GI toxicosis in dogs receiving toceranib

20 healthy dogs and 25 dogs with surgically excised MCT

Toceranib 2.75 mg/kg EOD

Mean plasma CK18 concentration on day 0?

A

No different than healthy dogs

Decreased by 98pg/mL from day 0 to 28 days

Not a clinically useful biomarker for GI toxicosis

112
Q

Henry et al. 2018. Clinical evaluation of Tavocept to decrease diuresis time and volume in dogs with bladder cancer receiving cisplatin

Tavocept is a chemoprotectant that has mitigated cisplatin toxicity and decreased diuresis in humans

14 dogs with TCC

Frequency of toxicity?

Diuresis time?

Response rate?

MST?

A

3 dogs (21%) had increase in creatinine and BUN and 2 of these were isisthenuric

Less

Less, from >6 hours to 90 minutes

27% which was inferioir to historical group

253 days vs. 246 days comparable to historical control

113
Q

Hess et al. 2018 Analysis of platinum content in biodegradable carboplatin-impregnated beads and retrospective assessment of tolerability for intralesional use of the beads in dogs following excision of SQ sarcomas: 29 cases

Mild to moderate local adverse events for 11/29 tumors (38%)

No systemic toxicosis

Local disease free rate 1-, 2-, 3-year - 70%, 70%, and 58%

A
114
Q

Miller et al. 2018. Suspected carboplatin extravasation reactions in 7 dogs

Wounds noted 7 days later

Healed with medical and surgical debridement median 25 days

Extravasation injury should be considered as possible local complication with carboplatin

A
115
Q

Richardson et al. 2018. Correlation between body weight and mitoxantrone-associated neutropenia in dogs

Mitoxantrone 5 mg/m2 IV

Grade 3 neutropenia and grade 4?

Dogs <10kg?

Dogs <15kg?

A

21% and 14%

More likely to develop grade 3 and 4 neutropenia

More likely to develop grade 3 and 4 neutropenia

Dose reduction should be considered in <10 kg dogs and increased risk of neutropenia in 10.1-15kg dogs

116
Q

Selting et al. 2018. Evaluation of intravenous and SQ administration of a novel, excipient free, nanoparticle formulation of paclitaxel in dogs with spontaneously occuring neoplasia

A
117
Q

Menard et al. 2018. Concurrent 5-FU and carboplatin for the treatment of canine carcinomas

24 dogs treated with 180-25 mg/m2 IV carbo and 5-FU 150 mg/m2

Common toxicity?

Response rate

A

14 dogs had myelosuppressoon - thrombocytopenia more common than neutropenia

GI signs were uncommon

43%

118
Q

Glutathione-S-transeferase theta genotypes and the risk of cyclophosphamide toxicity in dogs

A
119
Q

Borrensen et al. Liposomal encapsulated chemotherapy: Current evidence for its use in companinon animals

A
120
Q

Hwang et al. 2018. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occuring tumors

A

Literature (26 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions